Related Experiment Video
Updated: Apr 6, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Organelle-specific Hsp90 inhibitors
1College of Pharmacy, Keimyung University, Daegu, 704-701, Korea. seoyho@kmu.ac.kr.
Abstract:
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that is involved in the folding, activation, and stabilization of numerous oncogenic proteins. It has become an attractive therapeutic target, especially for eradicating malignant cancers and overcoming chemotherapy resistance. The Hsp90 family in mammalian cells is composed of four major homologs: Hsp90α, Hsp90β, 94-kDa glucose-regulated protein (Grp94), and TNF receptor-associated protein 1 (Trap1). Hsp90α and Hsp90β are mainly localized in the cytoplasm, while Grp94 and Trap1 reside in the endoplasmic reticulum and the mitochondria, respectively. Additionally, some Hsp90 s are secreted from the cytoplasm, commonly called extracellular Hsp90. Interestingly, each Hsp90 isoform is localized in a particular organelle, possesses a unique biological function, and participates in various physiological and pathological processes. To inhibit the organelle-specific Hsp90 chaperone function, there have been significant efforts to accumulate Hsp90 inhibitors in particular cellular compartments. This review introduces current studies regarding the delivery of Hsp90 inhibitors to subcellular organelles, particularly to the extracellular matrix and the mitochondria, and discusses their biological insights and therapeutic implications.
Insights
Heat shock protein 90 (Hsp90) inhibitors are being developed for targeted delivery to specific cellular compartments, enhancing cancer therapy and overcoming drug resistance.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Heat shock protein 90 (Hsp90) is a crucial molecular chaperone for oncogenic proteins.
- Hsp90 family includes Hsp90α, Hsp90β, Grp94, and Trap1, with distinct subcellular localizations.
- Hsp90's role in cancer and chemotherapy resistance makes it a significant therapeutic target.
Purpose of the Study:
- To review current strategies for delivering Hsp90 inhibitors to specific organelles.
- To discuss the biological insights and therapeutic potential of organelle-specific Hsp90 inhibition.
- To highlight advancements in targeting extracellular Hsp90 and mitochondrial Hsp90.
Main Methods:
- Review of existing literature on Hsp90 inhibitor delivery systems.
- Analysis of studies focusing on subcellular accumulation of Hsp90 inhibitors.
- Discussion of the functional consequences of organelle-specific Hsp90 inhibition.
Main Results:
- Significant efforts are underway to develop Hsp90 inhibitors that accumulate in specific cellular compartments.
- Targeting extracellular Hsp90 and mitochondrial Hsp90 shows promise for novel therapeutic approaches.
- Organelle-specific inhibition aims to enhance efficacy and reduce off-target effects.
Conclusions:
- Targeted delivery of Hsp90 inhibitors to subcellular organelles represents a promising strategy in cancer therapy.
- Further research into organelle-specific Hsp90 inhibition could lead to more effective treatments for various cancers.
- Understanding isoform-specific functions is key to developing potent and selective Hsp90-targeted drugs.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors of Bacterial Protein Synthesis
Molecular Chaperones and Protein Folding
The...
Molecular Chaperones and Protein Folding
Directing Proteins to the Rough Endoplasmic Reticulum
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

